Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
TAVR Highlights: New self-expanding valve shows promise | 4,000 TAVRs | How CAD & PCI affect outcomes
Thursday, February 16, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: TAVR

New self-expanding TAVR valve shows promise

It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device. 

READ MORE >
A team in China treated 10 patients—split evenly between men and women—with the SinoCrown TAVR valve developed by Lepu Medical Technology Company. The average patient age was 77.5 years old.
Share on Twitter Share on Facebook Share on Linkedin

New self-expanding TAVR valve shows promise

Share on Twitter Share on Facebook Share on Linkedin
A team in China treated 10 patients—split evenly between men and women—with the SinoCrown TAVR valve developed by Lepu Medical Technology Company. The average patient age was 77.5 years old.
It is still early for this new-look TAVR valve, but initial findings out of China include a procedural success rate of 100% and no deaths, disabling strokes or myocardial infarctions after 30 days. Read a full analysis from the team using the device. 
READ MORE >

New Jersey hospital performs 4,000th TAVR procedure

Morristown Medical Center first started performing TAVR procedures in 2011 and is now home to one of the largest TAVR programs in the United States. 

READ MORE >
Balloon expansion deployment of an Edwards Lifesciences Sapien 3 transcatheter aortic valve replacement (TAVR) device.
Share on Twitter Share on Facebook Share on Linkedin

New Jersey hospital performs 4,000th TAVR procedure

Share on Twitter Share on Facebook Share on Linkedin
Balloon expansion deployment of an Edwards Lifesciences Sapien 3 transcatheter aortic valve replacement (TAVR) device.
Morristown Medical Center first started performing TAVR procedures in 2011 and is now home to one of the largest TAVR programs in the United States. 
READ MORE >

How CAD, PCI affect TAVR outcomes among men and women

According to new research published in the American Journal of Cardiology, complex CAD appears to affect long-term TAVR outcomes much more for women than it does for men.   

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

How CAD, PCI affect TAVR outcomes among men and women

Share on Twitter Share on Facebook Share on Linkedin
According to new research published in the American Journal of Cardiology, complex CAD appears to affect long-term TAVR outcomes much more for women than it does for men.   
READ MORE >

TAVR and PAD: What cardiologists need to know

TAVR patients presenting with peripheral artery disease face significantly higher in-hospital risks, according to a new study published in Current Problems in Cardiology. 

READ MORE >
A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare. Sex differences in TAVR one-year mortality.
Share on Twitter Share on Facebook Share on Linkedin

TAVR and PAD: What cardiologists need to know

Share on Twitter Share on Facebook Share on Linkedin
A transcatheter aortic valve replacement (TAVR) procedure being performed at Intermountain Healthcare. Image from Intermountain Healthcare. Sex differences in TAVR one-year mortality.
TAVR patients presenting with peripheral artery disease face significantly higher in-hospital risks, according to a new study published in Current Problems in Cardiology. 
READ MORE >

Why are post-TAVR stroke rates higher at comprehensive stroke centers?

One of the more likely reasons is simple: specialty centers have better tools for identifying signs of stroke.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Why are post-TAVR stroke rates higher at comprehensive stroke centers?

Share on Twitter Share on Facebook Share on Linkedin
One of the more likely reasons is simple: specialty centers have better tools for identifying signs of stroke.
READ MORE >

VIDEO: Exploring the use of cerebral protection devices during TAVR

Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures. 

READ MORE >
Samir Kapadia, MD, chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at Cleveland Clinic, explains why he believes the results of the late-breaking PROTECTED TAVR testing the use of a TAVR cerebral protection device were positive, although it did not meet its primary endpoint.
Share on Twitter Share on Facebook Share on Linkedin

VIDEO: Exploring the use of cerebral protection devices during TAVR

Share on Twitter Share on Facebook Share on Linkedin
Samir Kapadia, MD, chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at Cleveland Clinic, explains why he believes the results of the late-breaking PROTECTED TAVR testing the use of a TAVR cerebral protection device were positive, although it did not meet its primary endpoint.
Samir Kapadia, MD, chair of the department of cardiovascular medicine at Cleveland Clinic, shared his perspective on the use of cerebral protection devices during TAVR procedures. 
READ MORE >

Greater access to TAVR linked to better patient outcomes

How does access to care influence short-term TAVR outcomes? Researchers explored data from nearly 22,000 patients to find out. 

READ MORE >
With advances and increased experience in the percutaneous coronary intervention (PCI), same-day discharge (SDD) has become increasingly commonplace, but patient selection is key. Antithrombotic therapy may not be necessary for certain transcatheter aortic valve replacement (TAVR) patients, according to a new analysis published in JACC: Cardiovascular Interventions.
Share on Twitter Share on Facebook Share on Linkedin

Greater access to TAVR linked to better patient outcomes

Share on Twitter Share on Facebook Share on Linkedin
With advances and increased experience in the percutaneous coronary intervention (PCI), same-day discharge (SDD) has become increasingly commonplace, but patient selection is key. Antithrombotic therapy may not be necessary for certain transcatheter aortic valve replacement (TAVR) patients, according to a new analysis published in JACC: Cardiovascular Interventions.
How does access to care influence short-term TAVR outcomes? Researchers explored data from nearly 22,000 patients to find out. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

New antiplatelet recommendations | Heart failure drug recalled | Imaging tech makes US debut | Conavi Medical's good news
Safety concerns lead to new recall | FDA approves surgical device | Parents in jail after obese son's death | A fraud warning
AI making an impact behind the scenes | New EARLY TAVR data | Americans keep poisoning themselves with semaglutide
Week in Review: TAVR vs. SAVR | FDA clears AI tech | Payment model confusion | Private equity & cardiology | Injuries after PCI
Heart surgery kits recalled | Sex-specific outcomes after TAVR & SAVR | A new risk calculator | FDA clears tricuspid valve
Thousands of heart surgery kits recalled | TAVR for AR linked to 'encouraging' data | Carotid IVL | Progress for new HCM drug
AI company founded by cardiologist makes big splash | Getting clinicians on the same page | Kidney injuries after PCI

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme